semaglutide and lamotrigine nejm Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential semaglutide and lamotrigine Safely Improves

For timing considerations, check our guide on the best time to take semaglutide

Electronic databases including PubMed, Embase, and Web of Science were searched from inception until August 2025 using keywords such as GLP-1 receptor agonist, diabetic retinopathy, glaucoma, age-related macular degeneration, ocular disease, and neuroprotection. The search focused on identifying preclinical studies, large-scale retrospective cohort studies, and post-hoc analyses of major clinical trials that evaluated the utility and potential mechanisms of GLP-1RAs in ophthalmic diseases

Cross-trial comparisons are inherently limited and do not establish that one approach produces better results than another

As demand grows, new research finds covering GLP-1 medications will drive up premiums for employer-provided coverage by as much as 14 percent , even when access is limited to patients with the highest need

Accessed June 2026

Amazons program focuses on GLP-1 receptor agonists, a class of medications originally developed for managing type 2 diabetes but now widely used for weight loss